Literature DB >> 11825939

Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.

Loredana Sarmati1, Emanuele Nicastri, Saverio G Parisi, Gabriella d'Ettorre, Giorgio Mancino, Pasquale Narciso, Vincenzo Vullo, Massimo Andreoni.   

Abstract

The aim of the study was to analyze the relationship between genotypic and phenotypic drug resistance profiles of human immunodeficiency virus type 1 (HIV-1) strains isolated from patients during double-analogue nucleoside therapy. A drug-resistant HIV strain was isolated from 20 out of 25 patients, with 16 (64%) subjects carrying a virus with multiple drug resistance mutations. The most frequent resistance mutations were M184V (18 isolates) and M41L (7 isolates). Discordance between the genotypic and phenotypic profile for at least one drug was detected in 16 out of 25 strains. Particularly, eight isolates had a discordant genotypic-phenotypic resistance pattern for two drugs and one isolate had such a pattern for three drugs. A genotypic resistance pattern with a phenotypic sensitivity profile was detected in six isolates (four resistant to zidovudine and two resistant to lamivudine). On the other hand for several strains a genotypic pattern of sensitivity pattern to abacavir (10 strains), didanosine (7 strains), stavudine (3 strains), zidovudine (2 strains), and lamivudine (1 strain) with a phenotypic resistance profile was detected. After a follow-up period of 8 months, an impairment of virological and immunological parameters was detected only in subjects with an HIV-1 isolate with a phenotypic resistance profile in despite of the genotypic results. Predicting resistance phenotype from genotypic data has important limitations. Despite the low number of patients and the short follow-up period, this study suggests that during failing therapy with analogue nucleosides, a phenotypic analysis could be performed in spite of an HIV genotypic sensitivity pattern.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825939      PMCID: PMC153419          DOI: 10.1128/JCM.40.2.335-340.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.

Authors:  M Andreoni; S G Parisi; L Sarmati; E Nicastri; L Ercoli; G Mancino; G Sotgiu; M Mannazzu; M Trevenzoli; G Tridente; E Concia; A Aceti
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

2.  Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.

Authors:  L Milazzo; S Rusconi; L Testa; S La Seta-Catamancio; M Galazzi; S Kurtagic; P Citterio; M Gianotto; A Grassini; F Adorni; A d'Arminio-Monforte; M Galli; M Moroni
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

3.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

Authors:  E P Coakley; J M Gillis; S M Hammer
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

4.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

5.  Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

Authors:  P F Lin; H Samanta; R E Rose; A K Patick; J Trimble; C M Bechtold; D R Revie; N C Khan; M E Federici; H Li
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

6.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

7.  Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.

Authors:  K Van Laethem; K Van Vaerenbergh; J C Schmit; S Sprecher; P Hermans; V De Vroey; R Schuurman; T Harrer; M Witvrouw; E Van Wijngaerden; L Stuyver; M Van Ranst; J Desmyter; E De Clercq; A M Vandamme
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

8.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

9.  A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Authors:  K Hertogs; M P de Béthune; V Miller; T Ivens; P Schel; A Van Cauwenberge; C Van Den Eynde; V Van Gerwen; H Azijn; M Van Houtte; F Peeters; S Staszewski; M Conant; S Bloor; S Kemp; B Larder; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

10.  Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.

Authors:  M Di Stefano; F Sabri; T Leitner; B Svennerholm; L Hagberg; G Norkrans; F Chiodi
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

View more
  4 in total

1.  The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.

Authors:  Neil T Parkin; Soumi Gupta; Colombe Chappey; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Dual-reporter phenotypic assay for human immunodeficiency viruses.

Authors:  Keiko Kajiwara; Eiichi Kodama; Yasuko Sakagami; Takeshi Naito; Masao Matsuoka
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

3.  Sensitivity to electrical stimulation of human immunodeficiency virus type 1 and MAGIC-5 cells.

Authors:  Etsuko Kumagai; Masato Tominaga; Shinji Harada
Journal:  AMB Express       Date:  2011-08-08       Impact factor: 3.298

4.  Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.

Authors:  Qinchang Zhu; Zhiqiang Yu; Tsutomu Kabashima; Sheng Yin; Shpend Dragusha; Ahmed F M El-Mahdy; Valon Ejupi; Takayuki Shibata; Masaaki Kai
Journal:  Sci Rep       Date:  2015-05-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.